Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-319 in Active Rheumatoid Arthritis
NCT07347860Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of A-319 in rheumatoid arthritis (RA). Primary endpoint: Safety and tolerability at 1 year. Started Jan 2026; status: recruiting.
02
Drugs
A-319
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07347860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347860.